Searchable abstracts of presentations at key conferences in endocrinology

ea0070s2.3 | Osteoporosis and fracture prediction | ECE2020

The role of bone turnover markers in the diagnosis and management of osteoporosis

Tsourdi Elena

During the last years, bone turnover markers (BTMs) have gained importance as surrogate markers to monitor both anti-resorptive and anabolic treatment, and may be used in conjunction with bone mineral density (BMD) measurements in clinical practice. The two most widely utilized BTMs are pro-collagen type 1 N-terminal propeptide (PINP), which reflects osteoblast activity, and C-terminal-cross-linking telopeptide of type 1 collagen (CTX), which corresponds to the osteoclastic fu...

ea0081rc8.6 | Rapid Communications 8: Calcium and Bone | ECE2022

Health related quality of life in adults with hypoparathyroidism in an exploratory analysis of the phase 2 PaTH forward trial of TransCon PTH

Palermo Andrea , Vokes Tamara J , Khan Aliya , Rubin Mishaela , Schwarz Peter , Clarke Bart L , Eriksen Erik , Marcocci Claudio , Pagotto Uberto , Tsourdi Elena , Sikjaer Tanja , Brod Meryl , Mcleod Lori , Markova Denka , Noori Wahidullah , Eng Walter Frank , Shu Aimee , Smith Alden

Background: Patients with hypoparathyroidism experience significant physical and cognitive symptoms and reduced health-related quality of life (HRQoL). Conventional therapy for hypoparathyroidism does not fully alleviate diminished HRQoL. The Hypoparathyroidism Patient Experience Scales (HPES) were developed to assess disease-specific physical and cognitive symptoms as well as the impact of hypoparathyroidsm on HRQol. TransCon PTH, an investigational long-acting prodrug of par...

ea0090p29 | Calcium and Bone | ECE2023

TransCon PTH Improves Health-Related Quality of Life and Reduces Work Limitations in Adults With Hypoparathyroidism: Patient-Reported Outcomes in the Phase 3 PaTHway Trial

Palermo Andrea , Khan Aliya , Rubin Mishaela , Schwarz Peter , Shoback Dolores M. , Gagnon Claudia , Cetani Filomena , Clarke Bart L. , Tsourdi Elena , Kohlmeier Lynn , Sikjaer Tanja , M Kaiser Stephanie , Lai Bryant , Le John , Ukena Jenny , Sibley Christopher , Shu Aimee , An Xubei , Noori Wahidullah , Smith Alden , Vokes Tamara J.

Background: Individuals with hypoparathyroidism often experience a range of symptoms associated with reduced health-related quality of life (HRQoL) and work productivity. Conventional therapy aims to alleviate hypocalcemia and acute symptoms but fails to restore normal parathyroid hormone (PTH) physiology or improve HRQoL. In the PaTHway trial, 79% of participants treated with TransCon PTH vs. 5% placebo (P<0.0001) met the primary efficacy endpoint (normal serum c...